Quick Answer
Relay Therapeutics, Inc. reported Net Income Loss of -$276.48 million for the year ending 2025.
- Relay Therapeutics, Inc. showed an increase of +18.1% in Net Income Loss from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$14.18 million | Q2 2019: -$17.54 million | Q3 2019: -$19.67 million | Q1 2020: -$24.89 million | Q2 2020: -$26.72 million | Q3 2020: -$36.08 million | Q1 2021: -$42.18 million | Q2 2021: -$193.40 million | Q3 2021: -$60.83 million | Q1 2022: -$62.05 million | Q2 2022: -$76.79 million | Q3 2022: -$84.17 million | Q1 2023: -$94.24 million | Q2 2023: -$98.51 million | Q3 2023: -$65.73 million | Q1 2024: -$81.39 million | Q2 2024: -$92.21 million | Q3 2024: -$88.11 million | Q1 2025: -$77.07 million | Q2 2025: -$70.38 million | Q3 2025: -$74.15 million.
- Over the full 7 years of available data (2019 to 2025), Relay Therapeutics, Inc.'s Net Income Loss has declined by 267.1%.
- Historical annual values: Fiscal year 2025: -$276.48 million | Fiscal year 2024: -$337.71 million | Fiscal year 2023: -$341.97 million | Fiscal year 2022: -$290.51 million | Fiscal year 2021: -$363.87 million | Fiscal year 2020: -$52.41 million | Fiscal year 2019: -$75.31 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: